Toronto, Canada — December 16, 2025 — Leads & Copy — Specific Biologics Inc. has appointed Dr. Richard Glickman to its Board of Directors.
Dr. Glickman, a biotechnology executive and entrepreneur, has over 30 years of experience in drug development, strategy and commercialization. He has founded or co-founded biopharmaceutical organizations, including StressGen Biotechnologies, Aspreva Pharmaceuticals, and Aurinia Pharmaceuticals, and has served on the boards of public and private biotechnology companies.
Specific Biologics is a precision in vivo genome editing company developing Dualase® genome editors. The company also announced that Frédéric Lemaître Auger will be stepping down from the Board of Directors.
Paul J. Hastings, Chair of the Board, and Brent Stead, CEO, commented on the appointment and transition.
Contact:
info@specificbiologics.com
Source: Specific Biologics Inc.
